A US-based KOL discusses the treatment of autism spectrum disorder, emphasizing a symptom-domain approach and the limitations of current pharmacological options. The KOL expresses skepticism about one-size-fits-all therapies and highlights interest in compounds targeting specific behaviors like mood dysregulation, inappropriate speech, and social deficits. 

This interview was conducted on December 02, 2025.

If you are a Datamonitor Healthcare client, you may access the interview from our KOL Insight channel.

If you are a KOL Insight subscriber, you may also access the interview from our KOL Insight portal.

Biomedtracker’s KOL Insight transcripts are available through subscription only. For more information on obtaining a KOL Insight subscription, please email Biomedtracker or call Biomedtracker Client Services at (888) 670-8900. 

For our disclosures, please read the Biomedtracker Research Standards.